Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus MONODOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus MONODOX.
ACTICLATE CAP vs MONODOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
100 mg orally or IV every 12 hours on day 1, then 100 mg orally or IV every 24 hours; for severe infections, 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life: 14-22 hours (mean ~18 hours) in adults; prolonged up to 24-48 hours in renal impairment; no dose adjustment in mild-moderate renal impairment but caution in severe (CrCl <30 mL/min).
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal: ~40% (glomerular filtration, tubular secretion); biliary: ~20-60% (enterohepatic circulation); fecal: ~30% (unabsorbed or excreted in bile).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic